Semler Scientific (NASDAQ:SMLR) Issues Earnings Results

Semler Scientific (NASDAQ:SMLR) announced its quarterly earnings results on Wednesday. The company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $1.21, FiscalAI reports. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.The company had revenue of $7.49 million during the quarter, compared to analysts’ expectations of $7.87 million.

Semler Scientific Stock Down 5.9%

Shares of NASDAQ SMLR traded down $1.62 during trading hours on Wednesday, hitting $25.73. The company had a trading volume of 928,424 shares, compared to its average volume of 793,651. Semler Scientific has a 1-year low of $21.84 and a 1-year high of $81.56. The company has a quick ratio of 0.58, a current ratio of 0.60 and a debt-to-equity ratio of 0.25. The firm’s 50 day moving average is $27.76 and its 200-day moving average is $33.44. The stock has a market capitalization of $389.60 million, a P/E ratio of 10.59 and a beta of 1.44.

Wall Street Analyst Weigh In

SMLR has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Semler Scientific in a research note on Wednesday, October 8th. Maxim Group lowered their price target on Semler Scientific from $95.00 to $80.00 and set a “buy” rating for the company in a report on Friday, September 19th. Benchmark cut their price objective on Semler Scientific from $101.00 to $86.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Finally, Cantor Fitzgerald lowered their target price on Semler Scientific from $61.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, August 6th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $74.25.

Institutional Investors Weigh In On Semler Scientific

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada grew its holdings in Semler Scientific by 101.2% during the first quarter. Royal Bank of Canada now owns 43,977 shares of the company’s stock worth $1,592,000 after purchasing an additional 22,123 shares during the period. AQR Capital Management LLC increased its holdings in shares of Semler Scientific by 71.7% during the 1st quarter. AQR Capital Management LLC now owns 15,251 shares of the company’s stock worth $552,000 after acquiring an additional 6,371 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Semler Scientific by 47.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,965 shares of the company’s stock valued at $144,000 after acquiring an additional 1,269 shares during the period. JPMorgan Chase & Co. lifted its holdings in Semler Scientific by 23.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,143 shares of the company’s stock valued at $160,000 after purchasing an additional 776 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Semler Scientific by 77.8% during the second quarter. Rhumbline Advisers now owns 13,191 shares of the company’s stock worth $511,000 after purchasing an additional 5,773 shares during the period. 49.37% of the stock is owned by institutional investors.

About Semler Scientific

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.